List/Grid

Oncology Subscribe to Oncology

Three-quarters of depressed cancer patients do not receive treatment for depression; new approach could transform care

Three-quarters of depressed cancer patients do not receive treatment for depression; new approach could transform care

Three papers published in The Lancet Psychiatry, The Lancet, and The Lancet Oncology reveal that around three-quarters of cancer patients who have major depression are not currently receiving treatment for depression, and that a new integrated treatment program is strikingly more effective at reducing depression and improving quality of life than current care. An analysis of data from more than 21,000 patients attending cancer clinics in Scotland, UK, published in The Lancet Psychiatry , found that major depression is substantially more common in cancer patients than in the general population Continue reading

Ovarian Cancer: Know your body, know your risk

Ovarian Cancer: Know your body, know your risk

Ovarian cancer is the fourth leading cause of death in American women, with about 22,000 diagnosed and 14,000 dying from the disease each year. Continue reading

Finding keys to glioblastoma therapeutic resistance

Finding keys to glioblastoma therapeutic resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas — the primary form of a deadly brain cancer — are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature Continue reading

High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer

High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA. EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available. A more abundant and less invasive source of tumor DNA may be cell free tumor DNA found circulating in the blood. Continue reading

Novel oncogenic RET mutation found in small cell lung cancer

Novel oncogenic RET mutation found in small cell lung cancer

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within SCLC cell lines produced increased intracellular signaling and cell growth. SCLC is a highly malignant form of lung cancer representing 15% of all lung cancers and is strongly associated with tobacco smoking Continue reading

Deletion predicts survival in advanced non-small cell lung cancer

Deletion predicts survival in advanced non-small cell lung cancer

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. Continue reading

Guidelines can predict early menopause in child cancer survivors, giving hope for fertility

Guidelines can predict early menopause in child cancer survivors, giving hope for fertility

Girls with cancer who are most likely to become infertile after treatment can be identified using guidelines developed almost 20 years ago, new research shows. Continue reading

Treatment developed by biologists shows promise in fighting fibrotic disease

Treatment developed by biologists shows promise in fighting fibrotic disease

A decade after first identifying serum amyloid P (SAP) as a key protein in human blood that controls routine tissue-related processes from scarring to healing, two Texas A&M University scientists and the biotechnology company they co-founded continue to make encouraging progress in the fight against fibrotic disease, a broad class of chronic conditions associated with an estimated 45 percent of U.S. deaths per year. Texas A&M biologists Richard Gomer and Darrell Pilling have collaborated in recent years on several SAP-related advances, from establishing Promedior Inc Continue reading

Treatment developed by biologists shows promise in fighting fibrotic disease

Treatment developed by biologists shows promise in fighting fibrotic disease

A decade after first identifying serum amyloid P (SAP) as a key protein in human blood that controls routine tissue-related processes from scarring to healing, two Texas A&M University scientists and the biotechnology company they co-founded continue to make encouraging progress in the fight against fibrotic disease, a broad class of chronic conditions associated with an estimated 45 percent of U.S. deaths per year. Texas A&M biologists Richard Gomer and Darrell Pilling have collaborated in recent years on several SAP-related advances, from establishing Promedior Inc Continue reading

Bone tumour destroyed using incisionless surgery: First in North American child

Bone tumour destroyed using incisionless surgery: First in North American child

A patient at The Hospital for Sick Children (SickKids) is the first child in North America to have undergone a specialized procedure that uses ultrasound and magnetic resonance imaging (MRI) to destroy a tumor in his leg without piercing the skin. Doctors used an MRI to guide high-intensity ultrasound waves to destroy a benign bone tumor called osteoid osteoma. Continue reading